The mechanism of SGLT2 inhibition in glucose control - PACE-CME

The mechanism of SGLT inhibition in glucose control

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Is GLP-1RA use harmful or safe in patients with HFrEF and obesity?
Is GLP-1RA use harmful or safe in patients with HFrEF and obesity?
ESC Heart Failure 2025
Is GLP-1RA use harmful or safe in patients with HFrEF and obesity?
- Varun Sundaram, MD, PhD
Expert opinion on the SOUL study results
Expert opinion on the SOUL study results
ACC.25
Expert opinion on the SOUL study results
- Gina Lundberg, MD
Semaglutide improves walking distance, symptoms and QoL in patients with PAD and T2D
Semaglutide improves walking distance, symptoms and QoL in patients with PAD and T2D
ACC.25
Semaglutide improves walking distance, symptoms and QoL in patients with PAD and T2D
- Marc Bonaca, MD
SBP target of lower than 120 mmHg reduces risk of CV events in T2DM
SBP target of lower than 120 mmHg reduces risk of CV events in T2DM
AHA 2024
SBP target of lower than 120 mmHg reduces risk of CV events in T2DM
- Shawna Nesbitt, MD